SONN: Sonnet BioTherapeutics Holdings Inc. Stocks News on July 4, 2024

SONN

GlobeNewswire

14 days ago

Sonnet BioTherapeutics Announces Exercise of Warrants for $3.4 Million in Gross Proceeds

SONN

GlobeNewswire

21 days ago

Sonnet BioTherapeutics Announces the Generation and Characterization of Two Novel Immunotherapeutic Pipeline Drug Candidates, SON-1411 and SON-1400, Each Containing a Variant IL-18 Domain

SONN

GlobeNewswire

a month ago

Sonnet BioTherapeutics to Present SB221 as a Trial in Progress at the ASCO 2024 Annual Meeting

SONN

ACCESSWIRE

a month ago

Sonnet BioTherapeutics Announces Review of Strategic Alternatives

SONN

ACCESSWIRE

a month ago

Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010 as Monotherapy or Combined with an anti-PD-L1, along with an Increase in the Dose-Escalation Target

SONN

ACCESSWIRE

2 months ago

Sonnet BioTherapeutics Provides Fiscal Year 2024 Second Quarter and Year-to-Date Business and Earnings Update

SONN

ACCESSWIRE

2 months ago

Sonnet BioTherapeutics Announces Participation in the EF Hutton Annual Global Conference

SONN

Newsfile

2 months ago

Sonnet BioTherapeutics Announces Participation in the EF Hutton Annual Global Conference

SONN

ACCESSWIRE

4 months ago

Sonnet BioTherapeutics to Present Preclinical Data on SON-080 for Chemotherapy-Induced Peripheral Neuropathy (CIPN) at the AACR 2024 Annual Meeting

SONN

ACCESSWIRE

4 months ago

Sonnet BioTherapeutics Announces Early Safety Data from the Company’s Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Met the Study’s Initial Pre-Specified Objective

SONN

ACCESSWIRE

4 months ago

Sonnet BioTherapeutics Announces a Publication Demonstrating Safety and Tolerability of SON-1010 in Healthy Volunteers

SONN

Simply Wall St.

5 months ago

Sonnet BioTherapeutics Holdings First Quarter 2024 Earnings: Beats Expectations

SONN

ACCESSWIRE

5 months ago

Sonnet BioTherapeutics Provides Fiscal Year 2024 First Quarter Business and Earnings Update

David Perry Bought 8.6% More Shares In Better Therapeutics

SONN

Simply Wall St.

6 months ago

David Perry Bought 8.6% More Shares In Better Therapeutics

Better Therapeutics Announces Publication of Cost-Effectiveness Analysis Demonstrating AspyreRx is More Effective and Less Costly than Standard of Care Alone

SONN

Business Wire

6 months ago

Better Therapeutics Announces Publication of Cost-Effectiveness Analysis Demonstrating AspyreRx is More Effective and Less Costly than Standard of Care Alone

EPOW’s CEO Purchased 245,000 Shares of the Company’s Ordinary Shares

SONN

GlobeNewswire

6 months ago

EPOW’s CEO Purchased 245,000 Shares of the Company’s Ordinary Shares

IHT DECLARES 54TH CONSECUTIVE ANNUAL DIVIDEND AS REVENUES CONTINUE TO CLIMB WITH RECORD DECEMBER

SONN

GlobeNewswire

6 months ago

IHT DECLARES 54TH CONSECUTIVE ANNUAL DIVIDEND AS REVENUES CONTINUE TO CLIMB WITH RECORD DECEMBER

Better Therapeutics and Glooko Announce Partnership to Accelerate Adoption of AspyreRx to Treat Type 2 Diabetes in the United States

SONN

Business Wire

6 months ago

Better Therapeutics and Glooko Announce Partnership to Accelerate Adoption of AspyreRx to Treat Type 2 Diabetes in the United States

Better Therapeutics Insiders Added US$6.57m Of Stock To Their Holdings

SONN

Simply Wall St.

6 months ago

Better Therapeutics Insiders Added US$6.57m Of Stock To Their Holdings

Better Therapeutics Announces Submission for FDA Breakthrough Device Designation for Digital Therapeutic Platform to Treat Liver Disease

SONN

Business Wire

6 months ago

Better Therapeutics Announces Submission for FDA Breakthrough Device Designation for Digital Therapeutic Platform to Treat Liver Disease

InnSuites Hospitality Trust Chairman James Wirth Acquires 1,500 Shares

SONN

GuruFocus.com

6 months ago

InnSuites Hospitality Trust Chairman James Wirth Acquires 1,500 Shares

Sunrise New Energy Receives Approval for Metal Sulfide-Doped Hard Carbon Composite Material Patent, Further Advancing Sodium Battery Material Frontier Technology

SONN

GlobeNewswire

6 months ago

Sunrise New Energy Receives Approval for Metal Sulfide-Doped Hard Carbon Composite Material Patent, Further Advancing Sodium Battery Material Frontier Technology

VS Media Announces Receipt of Nasdaq Minimum Bid Price Notification

SONN

GlobeNewswire

6 months ago

VS Media Announces Receipt of Nasdaq Minimum Bid Price Notification

Sunrise New Energy Full Year 2022 Earnings: US$0.98 loss per share (vs US$0.35 loss in FY 2021)

SONN

Simply Wall St.

6 months ago

Sunrise New Energy Full Year 2022 Earnings: US$0.98 loss per share (vs US$0.35 loss in FY 2021)

Sunrise New Energy Announces Breakthrough Achievement in Sodium-ion Battery Hard Carbon Composite Material with Approval of Invention Patent by National Intellectual Property Office

SONN

GlobeNewswire

6 months ago

Sunrise New Energy Announces Breakthrough Achievement in Sodium-ion Battery Hard Carbon Composite Material with Approval of Invention Patent by National Intellectual Property Office

Chairman James Wirth Acquires 2,000 Shares of InnSuites Hospitality Trust (IHT)

SONN

GuruFocus.com

6 months ago

Chairman James Wirth Acquires 2,000 Shares of InnSuites Hospitality Trust (IHT)

Sunrise New Energy Secures Highly Regarded Japanese Patent for Invention of Lithium-Ion Battery Anode Material Preparation Method

SONN

GlobeNewswire

6 months ago

Sunrise New Energy Secures Highly Regarded Japanese Patent for Invention of Lithium-Ion Battery Anode Material Preparation Method

SONN

ACCESSWIRE

6 months ago

Sonnet BioTherapeutics Announces Publication Demonstrating Suitability of SON-1210, the First Albumin-binding Bifunctional IL-12/IL-15 Fusion Protein, for Solid Tumor Immunotherapy

EPOW Lead in Establishing National Battery Industry Standard Policy, Highlighting Its Position as a Benchmark in Technological Innovation, Product Quality and Management Efficiency in the Industry

SONN

GlobeNewswire

6 months ago

EPOW Lead in Establishing National Battery Industry Standard Policy, Highlighting Its Position as a Benchmark in Technological Innovation, Product Quality and Management Efficiency in the Industry

SONN

ACCESSWIRE

7 months ago

Sonnet BioTherapeutics Provides Fiscal Year 2023 Business and Financial Update

SONN

Thomson Reuters StreetEvents

7 months ago

Q3 2023 Torrid Holdings Inc Earnings Call

IHT THIRD FISCAL QUARTER REVENUES INCREASE 7%

SONN

GlobeNewswire

7 months ago

IHT THIRD FISCAL QUARTER REVENUES INCREASE 7%

Insider Buying: Chairman James Wirth Acquires Shares of InnSuites Hospitality Trust (IHT)

SONN

GuruFocus.com

7 months ago

Insider Buying: Chairman James Wirth Acquires Shares of InnSuites Hospitality Trust (IHT)

20 Countries with the Highest Teenage Pregnancy Rates

SONN

Insider Monkey

7 months ago

20 Countries with the Highest Teenage Pregnancy Rates

PAVmed Inc. (NASDAQ:PAVM) Q3 2023 Earnings Call Transcript

SONN

Insider Monkey

7 months ago

Latest Sonnet BioTherapeutics Holdings Inc. (SONN) News on July 4, 2024

Sonnet BioTherapeutics Announces Exercise of Warrants for $3.4 Million in Gross Proceeds

Sonnet BioTherapeutics Announces the Generation and Characterization of Two Novel Immunotherapeutic Pipeline Drug Candidates, SON-1411 and SON-1400, Each Containing a Variant IL-18 Domain

Sonnet BioTherapeutics to Present SB221 as a Trial in Progress at the ASCO 2024 Annual Meeting

Sonnet BioTherapeutics Announces Review of Strategic Alternatives

Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010 as Monotherapy or Combined with an anti-PD-L1, along with an Increase in the Dose-Escalation Target

Sonnet BioTherapeutics Provides Fiscal Year 2024 Second Quarter and Year-to-Date Business and Earnings Update

Sonnet BioTherapeutics Announces Participation in the EF Hutton Annual Global Conference

Sonnet BioTherapeutics Announces Participation in the EF Hutton Annual Global Conference

Sonnet BioTherapeutics to Present Preclinical Data on SON-080 for Chemotherapy-Induced Peripheral Neuropathy (CIPN) at the AACR 2024 Annual Meeting

Sonnet BioTherapeutics Announces Early Safety Data from the Company’s Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Met the Study’s Initial Pre-Specified Objective

Sonnet BioTherapeutics Announces a Publication Demonstrating Safety and Tolerability of SON-1010 in Healthy Volunteers

Sonnet BioTherapeutics Holdings First Quarter 2024 Earnings: Beats Expectations

Sonnet BioTherapeutics Provides Fiscal Year 2024 First Quarter Business and Earnings Update

David Perry Bought 8.6% More Shares In Better Therapeutics

Better Therapeutics Announces Publication of Cost-Effectiveness Analysis Demonstrating AspyreRx is More Effective and Less Costly than Standard of Care Alone

EPOW’s CEO Purchased 245,000 Shares of the Company’s Ordinary Shares

IHT DECLARES 54TH CONSECUTIVE ANNUAL DIVIDEND AS REVENUES CONTINUE TO CLIMB WITH RECORD DECEMBER

Better Therapeutics and Glooko Announce Partnership to Accelerate Adoption of AspyreRx to Treat Type 2 Diabetes in the United States

Better Therapeutics Insiders Added US$6.57m Of Stock To Their Holdings

Better Therapeutics Announces Submission for FDA Breakthrough Device Designation for Digital Therapeutic Platform to Treat Liver Disease

InnSuites Hospitality Trust Chairman James Wirth Acquires 1,500 Shares

Sunrise New Energy Receives Approval for Metal Sulfide-Doped Hard Carbon Composite Material Patent, Further Advancing Sodium Battery Material Frontier Technology

VS Media Announces Receipt of Nasdaq Minimum Bid Price Notification

Sunrise New Energy Full Year 2022 Earnings: US$0.98 loss per share (vs US$0.35 loss in FY 2021)

Sunrise New Energy Announces Breakthrough Achievement in Sodium-ion Battery Hard Carbon Composite Material with Approval of Invention Patent by National Intellectual Property Office

Chairman James Wirth Acquires 2,000 Shares of InnSuites Hospitality Trust (IHT)

Sunrise New Energy Secures Highly Regarded Japanese Patent for Invention of Lithium-Ion Battery Anode Material Preparation Method

Sonnet BioTherapeutics Announces Publication Demonstrating Suitability of SON-1210, the First Albumin-binding Bifunctional IL-12/IL-15 Fusion Protein, for Solid Tumor Immunotherapy

EPOW Lead in Establishing National Battery Industry Standard Policy, Highlighting Its Position as a Benchmark in Technological Innovation, Product Quality and Management Efficiency in the Industry

Sonnet BioTherapeutics Provides Fiscal Year 2023 Business and Financial Update

Q3 2023 Torrid Holdings Inc Earnings Call

IHT THIRD FISCAL QUARTER REVENUES INCREASE 7%

Insider Buying: Chairman James Wirth Acquires Shares of InnSuites Hospitality Trust (IHT)

20 Countries with the Highest Teenage Pregnancy Rates

PAVmed Inc. (NASDAQ:PAVM) Q3 2023 Earnings Call Transcript

Share on Social Networks: